CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia
Open Access
- 2 May 2024
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 109 (9) , 3004-3008
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer ImmunotherapyACS Central Science, 2020
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid TumorsNew England Journal of Medicine, 2020
- Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer ImmunotherapyCancers, 2019
- CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemiaLeukemia, 2019
- Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activityLeukemia, 2017
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- The role of CD22 and Siglec-G in B-cell tolerance and autoimmune diseaseNature Reviews Rheumatology, 2014
- NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effectsBlood, 2010
- Umbilical cord blood transplantation: Basic biology and clinical challenges to immune reconstitutionClinical Immunology, 2008
- Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.Blood, 2007